Viridian Therapeutics
VRDN
57 hedge funds and large institutions have $71M invested in Viridian Therapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 9 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
0.05% less ownership
Funds ownership: 2.5% → 2.45% (-0.05%)
2% less capital invested
Capital invested by funds: $72.5M → $71M (-$1.47M)
3% less funds holding
Funds holding: 59 → 57 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.26M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.23M |
| 3 |
BWP
BSW Wealth Partners
Boulder,
Colorado
|
+$1.02M |
| 4 |
SG Americas Securities
New York
|
+$583K |
| 5 |
State Street
Boston,
Massachusetts
|
+$420K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$3.21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.11M |
| 3 |
Millennium Management
New York
|
-$185K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$142K |
| 5 |
SIM
Spark Investment Management
New York
|
-$64K |
VRDN Hedge Fund Activity: Q3 2018 in Review
57 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2018, worth a combined $71M — down 2% from $72.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VRDN and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 22 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.26M. The largest seller was 683 Capital Management, exiting entirely with an estimated $3.21M sold.
- 57 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2018, down from 59 in Q2 2018.
- Funds reported $71M of Viridian Therapeutics stock for Q3 2018, down 2% quarter-over-quarter.
- 7 funds opened new Viridian Therapeutics positions in Q3 2018 and 9 closed out, a net change of -2 holders.
- The largest Viridian Therapeutics buyer in Q3 2018 was Point72 Asset Management, an estimated $2.26M added.
- The largest Viridian Therapeutics seller in Q3 2018 was 683 Capital Management, an estimated $3.21M sold.
Based on aggregated 13F filings for Q3 2018.